Galecto Biotech AB-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Galecto Biotech AB - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8011900
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月13日
◆ページ数:17
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:デンマーク
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Galecto Biotech AB (Galecto Biotech) is a biotech company that focuses on the development of novel drugs for the treatment of fibrosis, inflammation, and other diseases. The company’s products act against galectins or galactoside binding lectins, a group of proteins that are involved in various disease processes. Galecto Biotech developed a series of galectin modulators, which demonstrated efficacy in various disease models, including fibrosis, inflammation and cancer. Its pipeline products include TD139 for idiopathic pulmonary fibrosis; Gal-200 for ocular fibrosis; and galectin-3 inhibitors such as Gal-300 for non-alcoholic steatohepatitis (NASH) and fibrosis, and Gal-400 for immuno-oncology. Galecto Biotech AB is headquartered in Lund, Sweden.

Galecto Biotech AB – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Galecto Biotech AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Galecto Biotech AB, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Galecto Biotech AB, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Galecto Biotech AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Galecto Biotech AB, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Galecto Biotech AB, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Galecto Biotech Secures Venture Funding from SEED Capital 10
Galecto Biotech Raises Additional Funds In Seed Financing 11
Partnerships 12
Edinburgh BioQuarter Enters Into Co-Development Agreement With Galecto Biotech 12
Acquisition 13
Bristol-Myers Squibb Enters into Option to Acquire Galecto Biotech and TD-139 13
Galecto Biotech AB – Key Competitors 14
Galecto Biotech AB – Key Employees 15
Galecto Biotech AB – Locations And Subsidiaries 16
Head Office 16
Appendix 17
Methodology 17
About GlobalData 17
Contact Us 17
Disclaimer 17

List of Tables
Galecto Biotech AB, Pharmaceuticals & Healthcare, Key Facts 2
Galecto Biotech AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Galecto Biotech AB, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Galecto Biotech AB, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Galecto Biotech AB, Deals By Therapy Area, 2011 to YTD 2017 8
Galecto Biotech AB, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Galecto Biotech Secures Venture Funding from SEED Capital 10
Galecto Biotech Raises Additional Funds In Seed Financing 11
Edinburgh BioQuarter Enters Into Co-Development Agreement With Galecto Biotech 12
Bristol-Myers Squibb Enters into Option to Acquire Galecto Biotech and TD-139 13
Galecto Biotech AB, Key Competitors 14
Galecto Biotech AB, Key Employees 15

★海外企業調査レポート[Galecto Biotech AB-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Dogus Otomotiv Servis ve Ticaret AS:戦略・SWOT・企業財務分析
    Dogus Otomotiv Servis ve Ticaret AS - Strategy, SWOT and Corporate Finance Report Summary Dogus Otomotiv Servis ve Ticaret AS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Compugen Ltd (CGEN):企業の財務・戦略的SWOT分析
    Summary Compugen Ltd (Compugen) is a predictive drug discovery and development company that develops medicines for immuno-oncology and autoimmune diseases. The company’s immuno-oncology pipeline comprises COM701 and PVRIG; BAY 1905254, COM902 and TIGIT; and autoimmune diseases pipeline includes CGEN …
  • Grupa Azoty SA (ATT):企業の財務・戦略的SWOT分析
    Grupa Azoty SA (ATT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Pegasystems Inc (PEGA):企業の財務・戦略的SWOT分析
    Pegasystems Inc (PEGA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Gas Malaysia Bhd (GASMSIA):企業の財務・戦略的SWOT分析
    Summary Gas Malaysia Bhd (Gas Malaysia) markets and distributes natural gas and liquefied petroleum gas (LPG). The company provides energy solutions which include power generation system with heat recovery such as power and combined heat; and alternative gas distribution such as virtual pipeline. It …
  • Gilead Sciences Inc (GILD):企業の財務・戦略的SWOT分析
    Gilead Sciences Inc (GILD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Rosseti (RSTI):企業の財務・戦略的SWOT分析
    Rosseti (RSTI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Global Telecom Holding SAE:企業の戦略的SWOT分析
    Global Telecom Holding SAE - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Caspian Energy Inc. (CKZ.H)-石油・ガス分野:企業M&A・提携分析
    Summary Caspian Energy Inc. (Caspian) is an independent upstream oil and gas company that explores for and develops hydrocarbon reserves, and produces oil and gas. Caspian and its subsidiaries hold interests in Aral Petroleum Capital LLP, which holds an exclusive license which entitles it to explore …
  • Denbury Resources Inc (DNR):企業の財務・戦略的SWOT分析
    Denbury Resources Inc (DNR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Hitachi Zosen Corp (7004):電力:M&Aディール及び事業提携情報
    Summary Hitachi Zosen Corp (Hitz) is an industrial and engineering company. It designs, constructs and operates refuse incineration and recycling facilities, pressure vessels, marine diesel engines, and press machines, and other process machine. The company also provides after-sales servicing and ma …
  • Max India Ltd:企業のM&A・事業提携・投資動向
    Max India Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Max India Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • Shiseido Company, Limited:企業の戦略・SWOT・財務分析
    Shiseido Company, Limited - Strategy, SWOT and Corporate Finance Report Summary Shiseido Company, Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Metorex Ltd:企業の戦略・SWOT・財務情報
    Metorex Ltd - Strategy, SWOT and Corporate Finance Report Summary Metorex Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Anadarko Petroleum Corp (APC):石油・ガス:M&Aディール及び事業提携情報
    Summary Anadarko Petroleum Corp (Anadarko) is an independent upstream oil and gas company, which carries out exploration, development, production, and marketing of natural gas, crude oil, condensate, and natural gas liquids (NGLs) from its assets. It also involves in gathering, processing, treating, …
  • Talisman Mining Ltd (TLM):企業の財務・戦略的SWOT分析
    Summary Talisman Mining Ltd (Talisman Mining) is a mining and mineral exploration and development company. The company explores for copper-gold, base metal, and gold deposits. Its projects portfolio includes Springfield project, Sinclair Nickel Project, Milgun Project, Halloween and Halloween West J …
  • Genera Biosystems Ltd (GBI):製薬・医療:M&Aディール及び事業提携情報
    Summary Genera Biosystems Ltd (GBL) is a multiplexed molecular diagnostic testing product developer. The company offers RTIplex and PapType molecular diagnostic test. Its RTIplex is a multiplexed and automated PCR based test for detection of viral and bacterial respiratory pathogens; and PapType is …
  • Boparan Holdings Ltd:企業の戦略的SWOT分析
    Boparan Holdings Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Vornado Realty Trust:企業の戦略・SWOT・財務分析
    Vornado Realty Trust - Strategy, SWOT and Corporate Finance Report Summary Vornado Realty Trust - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • MorphoSys AG (MOR)-製薬・医療分野:企業M&A・提携分析
    Summary MorphoSys AG (Morphosys) is a developer of monoclonal antibodies for therapeutic, diagnostic and research applications. The company’s pipeline product include MOR208, MOR202, MOR103, MOR209/ES414, MOR106, and MOR107, among others. It drugs are used in the treatment of different types of canc …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆